Skip to main content
Top

Cancer Immunology, Immunotherapy

Issue 6/1998

Content (8 Articles)

ORIGINAL ARTICLE

Immunogenicity of synthetic conjugates of Lewisy oligosaccharide with proteins in mice: towards the design of anticancer vaccines

Valery Kudryashov, Hyunjin M. Kim, Govindaswami Ragupathi, Samuel J. Danishefsky, Philip O. Livingston, K. O. Lloyd

ORIGINAL ARTICLE

Doxorubicin plus tumor necrosis factor α combination treatments in EL4-lymphoma-bearing C57BL/6 mice

M. J. Ehrke, Srdan Verstovšek, Peter Ujházy, Jane M. Meer, Cheryl Eppolito, Darbie L. Maccubbin, Enrico Mihich

ORIGINAL ARTICLE

Alteration of signal-transducing molecules in tumor-infiltrating lymphocytes and peripheral blood T lymphocytes from human colorectal carcinoma patients

S. H. Choi, Eun Joo Chung, Dae Yong Whang, Seung Sook Lee, Yong-Suk Jang, C. W. Kim

ORIGINAL ARTICLE

A novel glycoprotein obtained from Chlorella vulgaris strain CK22 shows antimetastatic immunopotentiation

K. Tanaka, Akira Yamada, Kiyoshi Noda, Takashi Hasegawa, Masao Okuda, Yukihiro Shoyama, Kikuo Nomoto

ORIGINAL ARTICLE

Parameters for using mannan-MUC1 fusion protein to induce cellular immunity

G. A. Pietersz, Wenjun Li, Violeta Popovski, Julie-Anne Caruana, Vasso Apostolopoulos, Ian F. C. McKenzie

ORIGINAL ARTICLE

FC-2.15, a monoclonal antibody active against human breast cancer, specifically recognizes Lewisx hapten

Mariana Capurro, Laura Bover, Paula Portela, Philip Livingston, J. Mordoh

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine